Who
Georgia Keresty
Director
Company insider
Files Form 4 as: Director, Solid Biosciences; Director, Intellia Therapeutics; Director, Aspentech.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 17 Apr 2019
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 12 Jun 2025filed 18 Jun 2025 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 11 Jun 2025filed 18 Jun 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,450 at $0.00 | filing |
| 11 Jun 2025filed 18 Jun 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,515 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —7,737 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,400 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —6,473 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —4,425 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 13 Dec 2022filed 15 Dec 2022 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —7,688 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —5,197 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 16 May 2022filed 18 May 2022 | Aspentechoption or derivative | SEC FORM 4 Code D | —1,684 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.